Similar articles

• Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes.

  Sherwood JK, Zeitlin L, Whaley KJ, Cone RA, Saltzman M. Sherwood JK, et al. Nat Biotechnol. 1996 Apr;14(4):468-71. doi: 10.1038/nbt0496-468. Nat Biotechnol. 1996. PMID: 9630921
• Acceptance and outcome of herpes simplex virus type 2 antibody testing in patients attending an STD clinic--recognized and unrecognized infections.

  Löwhagen GB, Berntsson M, Bonde E, Tunbäck P, Krantz I. Löwhagen GB, et al. Acta Derm Venereol. 2005;85(3):248-52. doi: 10.1080/00015550510025588. Acta Derm Venereol. 2005. PMID: 16040412
• Seroprevalence and determinants of herpes simplex type 2 infection in an STD clinic in Milan, Italy.

  Suligoi B, Calistri A, Cusini M, Palù G; Italian Herpes Management Forum. Suligoi B, et al. J Med Virol. 2002 Jul;67(3):345-8. doi: 10.1002/jmv.10072. J Med Virol. 2002. PMID: 12116025
• Clinical inquiries. What is the role of herpes virus serology in sexually transmitted disease screening?

  McCormack O, Carboy J, Nguyen L, Mercer J. McCormack O, et al. J Fam Pract. 2006 May;55(5):451-2. J Fam Pract. 2006. PMID: 16670044 Review. No abstract available.
• Role of herd immunity in determining the effect of vaccines against sexually transmitted disease.

  Garnett GP. Garnett GP. J Infect Dis. 2005 Feb 1;191 Suppl 1:S97-106. doi: 10.1086/425271. J Infect Dis. 2005. PMID: 15627236 Review.